A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.

Liang, Yayun; Mafuvadze, Benford; Besch-Williford, Cynthia; Hyder, Salman M

Liang, Yayun; Mafuvadze, Benford; Besch-Williford, Cynthia; Hyder, Salman M.

Afiliación

Liang Y; Deparment of Biomedical Sciences and Dalton Cardiovascular Research Center, Columbia, MO, USA.
Mafuvadze B; Deparment of Biomedical Sciences and Dalton Cardiovascular Research Center, Columbia, MO, USA.
Besch-Williford C; IDEXX BioResearch, Columbia, MO, USA.
Hyder SM; Deparment of Biomedical Sciences and Dalton Cardiovascular Research Center, Columbia, MO, USA.

Breast Cancer (Dove Med Press) ; 10: 53-67, 2018.

Article en En | MEDLINE | ID: mdl-29606888

Palabras clave

APR-246; angiogenesis; apoptosis; blood vessel targeting agent; breast cancer; p53

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer (Dove Med Press) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google